Evolus reported earnings-per-share results above analyst forecasts in its latest quarterly update, driving a 2.22% intraday gain. The beat underscores continued traction for Jeuveau, the company's botulinum toxin alternative, and reflects steady adoption among practices seeking competitive pricing and rebate incentives through the Evolus Rewards loyalty program.
Business & M&A
Evolus Beats EPS Forecast; Stock Rallies 2.22%
Neuromodulator maker posts earnings above expectations, signaling sustained demand for Jeuveau.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Evolus beats EPS forecast, signaling sustained demand for Jeuveau and rebate-driven adoption.
The positive surprise matters for independent practices weighing toxin sourcing. Evolus's financial strength directly correlates with its ability to fund aggressive rebate structures and maintain supply chain stability—both critical for practices locked into volume commitments. H.C. Wainwright maintained a Buy rating with a $13 price target, suggesting Wall Street sees runway. For practices currently on AbbVie or Galderma, Evolus's momentum is a reminder to stress-test your current per-unit economics against competitor offers.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.